Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Purpose This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.Materials and Methods The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.Results We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (<i>EGFR</i>) mutation (19% vs. 11%) or anaplastic lymphoma kinase (<i>ALK</i>) translocation (38% vs. 11%).Conclusion In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.
Abstract
Purpose This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.Materials and Methods The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.Results We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (<i>EGFR</i>) mutation (19% vs. 11%) or anaplastic lymphoma kinase (<i>ALK</i>) translocation (38% vs. 11%).Conclusion In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.
참고문헌 (27)
- Park S, "Lung cancer in Korea", J Thorac Oncol, 16, pp.1988~1993 (2021)
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
- Bar J, "Long-term survival of patients with metastatic non-small-cell lung cancer over five decades", J Oncol, 2021, pp.7836264~ (2021)
- Siegel RL, "Cancer statistics, 2022", CA Cancer J Clin, 72, pp.7~33 (2022)
- National Cancer Institute, "Surveillance, Epidemiology, and End Results program. SEER*Stat Database", National Cancer Institute, ~ (2021)
- Wong MC, "Incidence and mortality of lung cancer : global trends and association with socioeconomic status", Sci Rep, 7, pp.14300~ (2017)
- 김영철, "The Development of the Korean Lung Cancer Registry (KALC-R)", Tuberculosis and Respiratory Diseases, 82(2), pp.91~93 (2019), 대한결핵및호흡기학회[DOI]
- Dickman PW, "Estimating and modeling relative survival", Stata J, 15, pp.186~215 (2015)
- "Statistics Korea" (2020)[URL]
- 최창민, "Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014", Cancer Research and Treatment, 51(4), pp.1400~1410 (2019), 대한암학회
- Brundage MD, "Prognostic factors in non-small cell lung cancer : a decade of progress", Chest, 122, pp.1037~1057 (2002)
- Sachs E, "Sex and survival after surgery for lung cancer : a Swedish nationwide cohort", Chest, 159, pp.2029~2039 (2021)
- Albain KS, "Survival determinants in extensive-stage non-small-cell lung cancer : the Southwest Oncology Group experience", J Clin Oncol, 9, pp.1618~1626 (1991)
- Kawaguchi T, "Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer : a comprehensive analysis of 26, 957patients with NSCLC", J Thorac Oncol, 5, pp.620~630 (2010)
- Zhou K, "Association of race, socioeconomic factors, and treatment characteristics with overall survival in patients with limited-stage small cell lung cancer", JAMA Netw Open, 4, pp.e2032276~ (2021)
- Hong S, "Prognostic factors in small cell lung cancer : a new prognostic index in Korean patients", Oncology, 79, pp.293~300 (2010)
- Hiddinga BI, "Recent developments in the treatment of small cell lung cancer", Eur Respir Rev, 30, pp.210079~ (2021)
- Yoon SM, "Therapeutic management options for stage III non-small cell lung cancer", World J Clin Oncol, 8, pp.1~20 (2017)
- Spigel DR, "Five-year survival outcomes from the PACIFIC trial : durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer", J Clin Oncol, 40, pp.1301~1311 (2022)
- Yun JK, "Validation of the 8th edition of the TNM staging system in 3, 950 patients with surgically resected non-small cell lung cancer", J Thorac Dis, 11, pp.2955~2964 (2019)
- Akhtar-Danesh N, "Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada : a population-based study", Lung Cancer, 90, pp.8~14 (2015)
- Lu T, "Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades", Cancer Manag Res, 11, pp.943~953 (2019)
- 신애선, "Lung Cancer Epidemiology in Korea", Cancer Research and Treatment, 49(3), pp.616~626 (2017), 대한암학회
- Campos-Balea B, "Prognostic factors for survival in patients with metastatic lung adenocarcinoma : an analysis of the SEER database", Thorac Cancer, 11, pp.3357~3364 (2020)
- Giroux Leprieur E, "Factors associated with long-term survival of patients with advanced non-small cell lung cancer", Respirology, 17, pp.134~142 (2012)
- Lin JJ, "Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs", J Thorac Oncol, 11, pp.556~565 (2016)
- Huang CY, "Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma : a retrospective analysis", J Thorac Dis, 10, pp.2070~2078 (2018)